Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate

Background Methotrexate (MTX) is the first line of therapy for patients with juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). The mechanisms of action of MTX in childhood autoimmunity are not fully elucidated. The primary target sites of inflammation of JIA and JDM i.e. joint and muscle, respectively do not represent sites from which… CONTINUE READING